Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 9/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 4/20 | 0.31 |
| ▸ | YTHDF3 | Q7Z739 | 2/20 | 0.30 |
| ▸ | YTHDF1 | Q9BYJ9 | 2/20 | 0.30 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164390 | 0.84 | SLC29A1 (0.40) | CDK2CDK9CYP1A2CYP2C19LMNA | |
| SCHEMBL20164425 | 0.83 | YTHDC1 (0.38) | YTHDC1GAAP2RY1YTHDF3YTHDF1 | |
| SCHEMBL20164544 | 0.83 | YTHDC1 (0.40) | CDK2CDK9YTHDC1GAAP2RY1 | |
| SCHEMBL20164331 | 0.83 | YTHDC1 (0.40) | CDK2CDK9YTHDC1GAAP2RY1 | |
| SCHEMBL20164329 | 0.83 | YTHDC1 (0.40) | CDK2CDK9YTHDC1GAAP2RY1 | |
| SCHEMBL30560041 | 0.83 | YTHDC1 (0.40) | CDK2CDK9YTHDC1GAAP2RY1 | |
| Hydrochloric Acid SCHEMBL20164571 | 0.83 | SLC29A1 (0.40) | CDK2CDK9CYP1A2CYP2C19LMNA | |
| SCHEMBL20164785 | 0.81 | YTHDC1 (0.41) | YTHDC1P2RY1YTHDF3YTHDF1YTHDF2 | |
| SCHEMBL30560024 | 0.81 | YTHDC1 (0.41) | YTHDC1P2RY1YTHDF3YTHDF1YTHDF2 | |
| SCHEMBL30560025 | 0.81 | YTHDC1 (0.41) | CDK2CDK9YTHDC1P2RY1YTHDF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | CDK2 4026/4885CDK9 4092/4885YTHDC1 2024/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | CDK2 4190/4885CDK9 4292/4885YTHDC1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.